Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy

Among respiratory infections, tuberculosis was the second deadliest infectious disease in 2020 behind COVID-19. Inhalable nanocarriers offer the possibility of actively targeting anti-tuberculosis drugs to the lungs, especially to alveolar macrophages (cellular reservoirs of the Mycobacterium tuberc...

Descripción completa

Detalles Bibliográficos
Autores principales: Galdopórpora, Juan M., Martinena, Camila, Bernabeu, Ezequiel, Riedel, Jennifer, Palmas, Lucia, Castangia, Ines, Manca, Maria Letizia, Garcés, Mariana, Lázaro-Martinez, Juan, Salgueiro, Maria Jimena, Evelson, Pablo, Tateosian, Nancy Liliana, Chiappetta, Diego Andres, Moretton, Marcela Analia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145552/
https://www.ncbi.nlm.nih.gov/pubmed/35631546
http://dx.doi.org/10.3390/pharmaceutics14050959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145552/
https://www.ncbi.nlm.nih.gov/pubmed/35631546
http://dx.doi.org/10.3390/pharmaceutics14050959

Ejemplares similares